Seres Therapeutics (NASDAQ:MCRB – Get Rating) and Timber Pharmaceuticals (NYSE:TMBR – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations. Analyst Ratings This is a breakdown of current ratings […]
JPMorgan Chase & Co. began coverage on shares of Seres Therapeutics (NASDAQ:MCRB – Get Rating) in a research report sent to investors on Friday, The Fly reports. The brokerage issued a neutral rating and a $7.00 target price on the biotechnology company’s stock. A number of other equities analysts have also recently issued reports on […]
Wedbush Securities Inc. purchased a new position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,874 shares of the biotechnology company’s stock, valued at approximately $111,000. Several other hedge […]
Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) gapped up prior to trading on Tuesday . The stock had previously closed at $6.55, but opened at $6.83. Seres Therapeutics shares last traded at $6.44, with a volume of 788,140 shares trading hands. Analyst Upgrades and Downgrades MCRB has been the topic of a number of recent […]
Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) shares gapped up prior to trading on Tuesday . The stock had previously closed at $6.55, but opened at $6.83. Seres Therapeutics shares last traded at $6.44, with a volume of 788,140 shares. Analysts Set New Price Targets Several brokerages recently weighed in on MCRB. HC Wainwright reaffirmed […]